Osteomyelitis and Septic Arthritis in the Darwin Prospective Melioidosis Study
- PMID: 39758747
- PMCID: PMC11697087
- DOI: 10.1093/ofid/ofae741
Osteomyelitis and Septic Arthritis in the Darwin Prospective Melioidosis Study
Abstract
Background: Melioidosis is a multisystem infectious disease caused by the environmental bacterium Burkholderia pseudomallei. Osteomyelitis (OM) and septic arthritis (SA) are uncommon primary presentations for melioidosis but important secondary foci, often requiring prolonged therapy and multiple surgeries. We characterized the epidemiology, presentation, treatment, and outcomes of patients from 24 years of the Darwin Prospective Melioidosis Study (DPMS).
Methods: DPMS patients from October 1, 1999, until September 30, 2023, were included if they had a primary or secondary diagnosis of OM or SA. Epidemiological, risk factor, clinical, and outcome data were retrieved from the DPMS database. Antibiotic and surgical data were collated from patient records.
Results: From 1129 consecutive patients with culture-confirmed melioidosis, 122 (10.8%) had OM and/or SA, with 115 evaluable. Ninety-four of 1129 (8.3%) had OM, and 62/1129 (5.5%) had SA, with 41/115 (35.7%) of these having both OM and SA. Many combined infections involved contiguous bone and joints or soft tissue. Fifty-nine (51.3%) were male, and only 4.3% were ≤16 years old. Diabetes mellitus was present in 69.6%, and only 12.2% had no identifiable clinical risk factor. There were 8 deaths (7.0%) and 20 (17.4%) recurrent infections. Seventy-one (61.7%) had operative management, with combined infection associated with more procedures and longer length of stay.
Conclusions: The current paradigm of care for osteoarticular melioidosis involves prolonged intravenous antibiotics in conjunction with timely and complete operative management, and in our setting where these are available, outcomes are good. In many melioidosis-endemic regions these resources are limited, and mortality remains high.
Keywords: Burkholderia pseudomallei; bone and joint infection; melioidosis; osteomyelitis; septic arthritis.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. The authors declare no conflicts of interest.
Figures


References
-
- Meumann EM, Limmathurotsakul D, Dunachie SJ, Wiersinga WJ, Currie BJ. Burkholderia pseudomallei and melioidosis. Nat Rev Microbiol 2024; 22:155–69. - PubMed
-
- Yee KC, Lee MK, Chua CT, Puthucheary SD. Melioidosis, the great mimicker: a report of 10 cases from Malaysia. J Trop Med Hyg 1988; 91:249–54. - PubMed
-
- Currie BJ, Mayo M, Ward LM, et al. The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. Lancet Infect Dis 2021; 21:1737–46. - PubMed
-
- Shetty RP, Mathew M, Smith J, Morse LP, Mehta JA, Currie BJ. Management of melioidosis osteomyelitis and septic arthritis. Bone Joint J 2015; 97-B:277–82. - PubMed
LinkOut - more resources
Full Text Sources